India to Mauritius: Adalimumab Export Trade Route

To import Adalimumab formulations into Mauritius, the following approvals and registrations are mandatory:

• Product Registration: All pharmaceutical products must be registered with the National DRA before importation. This involves submitting a comprehensive dossier detailing the product's quality, safety, and efficacy.

• Dossier Format: The Common Technical Document (CTD) format is typically required for submissions.

• Approval Timelines: The approval process duration can vary; however, applicants should anticipate a period of several months for thorough evaluation.

• Registration Fees: Specific fees are associated with the registration process.

• GMP Inspection Requirements: Manufacturing facilities, including those in India, must comply with Good Manufacturing Practice (GMP) standards. The National DRA may require GMP certificates issued by recognized health authorities or conduct its own inspections to ensure compliance.

Indian manufacturers exporting Adalimumab formulations to Mauritius must adhere to the following GMP standards:

• GMP Certification: Facilities must possess valid GMP certificates, preferably issued by the Central Drugs Standard Control Organisation (CDSCO) of India or other recognized authorities.

• Approved Facilities: Only manufacturing sites that meet the National DRA's GMP standards are approved for export to Mauritius.

• Recent Inspections and Regulatory Actions: The National DRA maintains oversight of imported pharmaceuticals. While specific recent inspections or regulatory actions against Indian pharmaceutical companies are not publicly detailed, compliance with GMP standards is continually monitored to ensure product quality and safety.

In the past 18 months, several regulatory developments have impacted Indian pharmaceutical exports to Mauritius:

• Revised GMP Standards: In November 2025, the Drugs Controller General of India (DCGI) directed state drug regulators to enforce updated Good Manufacturing Practices under Schedule M of the Drugs and Cosmetics Act by January 2026. This revision aligns India's pharmaceutical manufacturing norms with global standards, potentially affecting exports to Mauritius.

• Mutual Recognition Agreements: As of March 2026, there have been no publicly announced mutual recognition agreements between Mauritius and India concerning pharmaceutical products.

• Policy Shifts: Mauritius continues to emphasize stringent quality control measures for imported pharmaceuticals. Importers and exporters must stay informed about any policy changes to ensure compliance with the National DRA's requirements.

Staying updated with these regulatory changes is crucial for maintaining uninterrupted pharmaceutical trade between India and Mauritius.

As of 2024, Mauritius's market for Adalimumab formulations is modest, reflecting the country's small population of approximately 1.3 million. The demand for Adalimumab is primarily driven by the prevalence of autoimmune diseases such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. The aging population and increased healthcare spending contribute to the demand for such biologic therapies. Mauritius relies heavily on imports for its pharmaceutical needs, including Adalimumab formulations, due to limited domestic manufacturing capabilities in this sector.

Mauritius maintains a liberalized trade regime with import tariffs ranging from zero to 100 percent. Pharmaceutical products under HS code 30021500, which includes Adalimumab formulations, are subject to a 0% Most-Favored-Nation (MFN) import duty. Additionally, a 15% Value Added Tax (VAT) is applied to most imported goods, including pharmaceuticals. Mauritius is a member of the Common Market for Eastern and Southern Africa (COMESA), which may offer preferential trade terms for member countries. However, specific details regarding Free Trade Agreements (FTAs) between India and Mauritius affecting pharmaceutical tariffs are not specified.

India is a significant supplier of Adalimumab formulations to Mauritius, accounting for 1.6% of India's total Adalimumab formulation exports, valued at $1.2 million. The top Indian exporters to Mauritius include GENEX PHARMA, MEDICOS LIFESCIENCES, and RELIANCE LIFE SCIENCES PRIVATE LIMITED. Other major countries supplying Adalimumab to Mauritius are not specified in the available data. India's competitive pricing, supported by its robust pharmaceutical manufacturing sector, positions it favorably against competitors from regions like China and the European Union.

India is a global leader in generic pharmaceutical production, accounting for approximately 20% of the global supply by volume as of 2025. This extensive manufacturing base includes numerous facilities producing finished dosage forms containing Adalimumab, such as injections. The country's cost-effective production is attributed to economies of scale, competitive labor costs, and a well-established supply chain for pharmaceutical ingredients. As of 2025, India boasts over 1,400 WHO-GMP certified manufacturing facilities and more than 800 US FDA-approved plants, many of which are equipped to produce Adalimumab formulations.

When comparing Adalimumab formulations from India, China, and the European Union (EU), several factors come into play:

• Price per Unit: In India, the average price for a 40 mg prefilled syringe of Adalimumab is approximately ₹7,500 (around $100) as of December 2025. In China, biosimilars are priced at about 82% of the reference drug's cost, translating to approximately $410 per 40 mg dose. In the EU, branded versions can cost upwards of $1,500 per 40 mg dose.

• Quality Perception: Indian pharmaceutical manufacturers adhere to stringent international standards, with many facilities holding WHO-GMP and US FDA certifications. Chinese manufacturers have improved quality standards but may face lingering perceptions of inconsistency. EU manufacturers are generally perceived as high-quality producers, often reflected in their higher pricing.

• Regulatory Acceptance in Mauritius: Mauritius recognizes and accepts pharmaceuticals from WHO-GMP certified facilities, which many Indian manufacturers possess. Chinese and EU products are also accepted, provided they meet the necessary regulatory standards.

• Supply Reliability Track Record: Indian manufacturers have a strong track record of supplying pharmaceuticals to Mauritius, with established logistics and distribution networks. Chinese suppliers are expanding their presence, while EU suppliers are known for reliability but at higher costs.

The India-Mauritius supply chain for Adalimumab formulations is robust, supported by India's substantial manufacturing capacity. Facilities such as Taj Pharma India Ltd. have a monthly production capacity of 120 million tablets and 40 million capsules, indicating significant capability to meet demand. These facilities are equipped with advanced packaging and cold chain logistics to ensure product integrity during transit. As of March 2026, there have been no significant supply disruptions reported in this route. Indian manufacturers maintain a strong regulatory compliance record, with numerous facilities holding WHO-GMP and US FDA certifications. While some manufacturers are expanding capacities, current production levels are sufficient to meet existing demand.

For Mauritius buyers sourcing Adalimumab from India, consider the following strategies:

• Dual-Sourcing Strategy: Engage with multiple WHO-GMP certified Indian manufacturers to mitigate risks associated with supply disruptions.

• Minimum Order Quantities (MOQs): Negotiate MOQs that align with your demand forecasts to optimize inventory levels and reduce holding costs.

• Payment Terms: Standard payment terms in India-Mauritius pharmaceutical trade often include a 30-60 day credit period; negotiate terms that support your cash flow requirements.

• Supplier Qualification Process: Conduct thorough due diligence, including facility audits and compliance checks, to ensure suppliers meet regulatory and quality standards.

• Regulatory Compliance: Ensure that the selected suppliers' products are registered and approved by Mauritius health authorities to facilitate smooth importation and distribution.

Before placing the first order with an Indian Adalimumab supplier, Mauritius buyers should adhere to the following checklist:

Prior to ordering Adalimumab formulations from India, Mauritius buyers should request the following documents:

When evaluating an Indian Adalimumab supplier, be vigilant for the following warning signs:

Conducting thorough audits and establishing ongoing monitoring are crucial for ensuring supplier compliance:

Cost Estimates and Timeline:

• Audit Visits to India:
• Plan for a 3-5 day on-site audit, including travel time.
• Estimated cost: $5,000 to $10,000 USD, covering auditor fees, travel, accommodation, and incidental expenses.

• Remote Monitoring:
• Ongoing costs will vary based on the frequency and depth of remote assessments but are generally lower than on-site audits.

By meticulously following these guidelines, Mauritius companies can ensure that their Indian Adalimumab suppliers meet the necessary quality and regulatory standards, thereby safeguarding public health and maintaining compliance with local and international regulations.